share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K:重大事件
美股sec公告 ·  06/24 16:07
Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc. announced on June 24, 2024, the appointment of Paul Varki as the company's new Chief Legal Officer. Varki, aged 52, brings over two decades of legal experience in the pharmaceutical industry to Avalo Therapeutics. His previous roles include General Counsel at Idorsia Pharmaceuticals US Inc., Vice President of Legal at Amarin Corporation plc, and senior legal positions at Braeburn Pharmaceuticals and Egalet Pharmaceuticals. Varki's extensive background also includes various legal roles at GlaxoSmithKline and practice in FDA regulatory law. His academic credentials include a J.D. from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary. Alongside his appointment, Varki entered into an employment agreement with Avalo Therapeutics, which includes a base salary, potential bonuses, and equity incentives. The agreement also outlines severance benefits and restrictive covenants. Avalo Therapeutics is a clinical-stage biotechnology company focusing on immune dysregulation treatments, with AVTX-009 as its lead asset targeting inflammatory diseases.
Avalo Therapeutics, Inc. announced on June 24, 2024, the appointment of Paul Varki as the company's new Chief Legal Officer. Varki, aged 52, brings over two decades of legal experience in the pharmaceutical industry to Avalo Therapeutics. His previous roles include General Counsel at Idorsia Pharmaceuticals US Inc., Vice President of Legal at Amarin Corporation plc, and senior legal positions at Braeburn Pharmaceuticals and Egalet Pharmaceuticals. Varki's extensive background also includes various legal roles at GlaxoSmithKline and practice in FDA regulatory law. His academic credentials include a J.D. from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary. Alongside his appointment, Varki entered into an employment agreement with Avalo Therapeutics, which includes a base salary, potential bonuses, and equity incentives. The agreement also outlines severance benefits and restrictive covenants. Avalo Therapeutics is a clinical-stage biotechnology company focusing on immune dysregulation treatments, with AVTX-009 as its lead asset targeting inflammatory diseases.
Avalo Therapeutics,Inc.於2024年6月24日宣佈任命Paul Varki爲公司的新首席法務官。52歲的Varki在藥品行業擁有超過20年的法律經驗,曾擔任Idorsia Pharmaceuticals US Inc.的總法律顧問,Amarin Corporation plc的法律副總裁,以及Braeburn Pharmaceuticals和Egalet Pharmaceuticals的高級法律職位。Varki廣泛的背景還包括在葛蘭素史克的各種法律角色和FDA監管法律實踐。他的學術證書包括來自天普大學法學院的JD學位,來自喬治華盛頓大學的公共衛生碩士學位以及來自威廉和瑪麗...展開全部
Avalo Therapeutics,Inc.於2024年6月24日宣佈任命Paul Varki爲公司的新首席法務官。52歲的Varki在藥品行業擁有超過20年的法律經驗,曾擔任Idorsia Pharmaceuticals US Inc.的總法律顧問,Amarin Corporation plc的法律副總裁,以及Braeburn Pharmaceuticals和Egalet Pharmaceuticals的高級法律職位。Varki廣泛的背景還包括在葛蘭素史克的各種法律角色和FDA監管法律實踐。他的學術證書包括來自天普大學法學院的JD學位,來自喬治華盛頓大學的公共衛生碩士學位以及來自威廉和瑪麗學院的文學學士學位。與他的任命同時,Varki與Avalo Therapeutics簽訂了僱傭協議,其中包括基本工資、獎金、股權激勵。協議還概述了分離福利和限制契約。Avalo Therapeutics是一家臨床階段的生物技術公司,專注於免疫失調治療,其領先資產AVTX-009針對炎症性疾病。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息